C
China Resources Pharmaceutical Group Ltd
HKEX:3320
China Resources Pharmaceutical Group Ltd
HKEX:3320
Price:
5.64
HKD
5.82%
Market Cap:
HK$35.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
HK |
|
Permanent TSB Group Holdings PLC
OTC:ILPMY
|
IE |
|
Straumann Holding AG
SIX:STMN
|
CH |
|
A
|
Aurum Pacific (China) Group Ltd
HKEX:8148
|
HK |
|
A
|
AQ Group AB
STO:AQ
|
SE |
|
Mirza International Ltd
NSE:MIRZAINT
|
IN |
|
S
|
Suzhou Douson Drilling&Production Equipment Co Ltd
SSE:603800
|
CN |
|
T
|
Tianju Dihe Suzhou Technology Co Ltd
HKEX:2479
|
CN |
|
Eastman Kodak Co
NYSE:KODK
|
US |
|
G
|
Grand Korea Leisure Co Ltd
KRX:114090
|
KR |
|
W
|
Wizz Air Holdings PLC
OTC:WZZZY
|
CH |
|
G
|
Gansu Mogao Industrial Development Co Ltd
SSE:600543
|
CN |
|
Supreme Engineering Ltd
NSE:SUPREMEENG
|
IN |
|
Skue Sparebank
OSE:SKUE
|
NO |
|
F
|
Fulongma Group Co Ltd
SSE:603686
|
CN |
Multiples-Based Value
The Multiples-Based Value of one China Resources Pharmaceutical Group Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 5.64 HKD, China Resources Pharmaceutical Group Ltd is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
China Resources Pharmaceutical Group Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
China Resources Pharmaceutical Group Ltd Competitors
China Resources Pharmaceutical Group Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| HK |
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
33.5B HKD | 0.1 | 8.5 | 0.9 | 1.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
